Designed for precision. Engineered for safety. Built for efficient production
BiOMViS is developing an integrated OMV-based vaccine platform designed to address three key challenges: vesicle composition, antigen loading and manufacturing efficiency.
By combining engineered bacterial strains, precision antigen engineering and streamlined OMV recovery, BiOMViS aims to enable more controlled design of OMV-based vaccine candidates.
Engineered OMV-Producing Strains
Proteome-Reduced OMVs. Engineered for Safety
BiOMViS has developed a proprietary collection of genetically engineered E. coli strains designed to address two key challenges in OMV-based vaccine development: endogenous protein content and safety.
A tailored vesicle composition. By reducing selected endogenous bacterial proteins, the BiOMViS platform is designed to minimize non-target protein content, creating greater capacity for selected vaccine antigens and enabling a more focused antigenic composition.
Safety by design. BiOMViS incorporates targeted genetic engineering strategies designed to support the development of OMVs with tailored safety profiles, providing a foundation for the development of next-generation vaccine candidates.
Precision Engineering of OMVs
Maximizing Antigen Loading. Enabling Targeted Vaccine Design
BiOMViS has developed proprietary antigen-engineering technologies that leverage bacterial lipoprotein transport and membrane-localization mechanisms to promote the incorporation of selected vaccine antigens into OMVs.
By combining engineered lipidated antigens with proteome-minimized OMVs, the platform is designed to maximize antigen representation and enable more targeted vesicle composition.
Up to 30% of Total OMV Protein Content
BiOMViS platform data demonstrate the potential to achieve high levels of antigen incorporation, supporting the development of differentiated OMV-based vaccine candidates.
Streamlined OMV Manufacturing
From Fermentation to Recovery. Designed for Process Development
BiOMViS combines engineered bacterial strains with a streamlined process for OMV generation and recovery.
The streamlined workflow is designed to facilitate technology transfer and support scalable manufacturing, providing a foundation for the advancement of OMV-based vaccine candidates.
Redefining the Potential of OMV-Based Vaccines
BiOMViS integrates engineered bacterial strains, precision antigen engineering and streamlined manufacturing into a unified technology platform designed to advance the development of next-generation vaccines.